Idorsia has secured bridge financing in the amount of CHF 75 million
20 Giugno 2023 - 7:00AM
Idorsia has secured bridge financing in the amount of CHF 75
million
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – June
20, 2023
Idorsia Ltd (SIX: IDIA) today announced that it has secured
bridge financing in the amount of CHF 75 million to extend the
company’s cash runway until the end of July and in the meantime
allow the completion of the recently announced prospective
strategic transaction for its Asia Pacific (ex-China)
operations, which is subject to completion of satisfactory due
diligence and legal documentation. The credit facility has been
provided by Jean-Paul Clozel, CEO, Member of the Board of Directors
and Idorsia’s largest shareholder.
Notes to the editor
About IdorsiaIdorsia Ltd is reaching out for
more – We have more ideas, we see more opportunities and we want to
help more patients. In order to achieve this, we will develop
Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 20-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe, Japan, and
the US – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 1,300 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please
contactAndrew C. WeissSenior Vice President, Head
of Investor Relations & Corporate CommunicationsIdorsia
Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58
844 10 10investor.relations@idorsia.commedia.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Grafico Azioni Idorsia (LSE:0RQE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Idorsia (LSE:0RQE)
Storico
Da Mag 2023 a Mag 2024